AOD-9604: The Fat-Loss Peptide That Didn't Pan Out
A growth-hormone fragment trialed for obesity in 500+ adults. The Phase IIb result is the part marketing omits.
AOD-9604 has an unusually instructive history for a peptide still sold online. It was not a back-alley compound. It was a genuine pharmaceutical candidate, developed by Metabolic Pharmaceuticals and tested in real clinical trials for obesity. And then it failed to deliver, which is precisely the part the marketing leaves out.
Where it came from
AOD-9604 is a fragment of human growth hormone — specifically the C-terminus, described in the published literature as Tyr-hGH177-191, with an added tyrosine for stability. The thinking was elegant: growth hormone has fat-mobilizing effects, but it also raises blood sugar and disrupts metabolism in ways you would not want in an obesity drug. Isolate just the lipolytic fragment, the reasoning went, and you might get the fat loss without the baggage.
That part held up on safety. A 2013 pooled analysis by Stier and colleagues in the Journal of Endocrinology and Metabolism, covering roughly 900 participants across six trials, found AOD9604 had a safety and tolerability profile indistinguishable from placebo, with no effect on IGF-1 levels and no negative effect on carbohydrate metabolism — unlike full-length growth hormone. So far, so clean.
What the human trials showed
Safety, however, is not efficacy. An early 12-week Phase IIa study reported encouraging weight loss in a low-dose group versus placebo. But the result that decides a drug’s fate is the larger confirmatory trial — and that is where AOD-9604 came apart.
In its pivotal 24-week Phase IIb trial of more than 500 obese adults, AOD-9604 failed to produce statistically significant weight loss versus placebo. Metabolic Pharmaceuticals discontinued development as an obesity drug in 2007.
That is why it never advanced to approval. It is not that the compound was dangerous and pulled — its safety record was, if anything, its strongest feature. It is closer to the more common scientific outcome: a promising mechanism that simply failed to do the job in people.
Why this matters for what you see online
AOD-9604 is still marketed, often emphasizing its growth-hormone pedigree and animal-study fat-burning effects while omitting the human trial outcome.
- The selling point is mechanism, not measured weight loss.
- The decisive human efficacy data is disappointing.
- Products sold today are not held to the testing standards the original drug candidate was.
The takeaway
AOD-9604 is not mysterious or suppressed. It was tested as an obesity drug in hundreds of people, proved safe, and largely did not work for weight loss — which is why you do not hear physicians prescribing it for that purpose. When a peptide’s pitch leans heavily on its origins and safety while staying quiet about efficacy, that silence is usually the most important data point.